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ABSTRACT: Objective: To determine if mental health service utilization increases
when patients are converted to generic clozapine. Method: About 125 patients taking
clozapine in a community mental health clinic were switched from Novartis Clozaril to
generic clozapine (Mylan Pharmaceuticals). Serum clozapine levels were obtained
2 weeks before, and 2 weeks after, the switch to generic clozapine. The number of
outpatient visits, emergency room visits, and hospitalizations in the year prior to the
switch were compared to those in the year following the switch, to determine service
utilization. Results: Psychiatric emergency room visits decreased, but clozapine serum
levels, inpatient hospital days, partial hospital admissions, and outpatient psychiatrist
visits did not change after the switch to generic clozapine. Conclusions: There were no
significant increases in mental health service utilization after the conversion to Mylan
generic clozapine. The switch to Mylan generic clozapine was cost effective, as the
reduction in pharmacy costs was not offset by increased utilization costs.
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INTRODUCTION
Clozapine is the preferred antipsychotic treatment for patients with
treatment refractory schizophrenia (Expert Consensus Guidelines,
2003) but the high cost of this therapy has made the use of generic
formulations of the drug very appealing. However, several recent re-
ports have suggested that patients switched to generic clozapine may
experience symptom exacerbation or lower serum levels on a generic
formulation (Kluznik, Walbek, Farnsworth, Melstrom, 2001; Mofsen &
Balter, 2001). This is undesirable from a clinical standpoint, as well as
from a budgetary standpoint; more money may be spent on clinical
delivery services than is saved from the cost of the medication.
Therefore, we examined mental health services utilization in patients
during the year before and the year after a switch from Novartis
Clozaril to Mylan generic clozapine to determine if service utilization
increases with the use of generic clozapine.
METHOD
Patients 18 years of age and older, in a Clozapine Clinic in a community mental health
setting were all switched from brand-name clozapine (Clozaril[registered], Novartis) to
generic clozapine (Mylan Pharmaceuticals) in January, 2001. This decision was made by
Washtenaw County Community Mental Health (CMH) and the University of Michigan
Pharmacy Service to reduce pharmacy costs, and Mylan was selected based on Mylan
Pharmaceuticals’ data on the comparable bioavailability of this preparation. Patients
had blood drawn for clozapine levels 2 weeks before, and 2 weeks after, the switch to
generic clozapine, as part of the quality assurance measurements taken by Washtenaw
County CMH. These levels were drawn at the same time as the routine white blood count
levels were drawn, so there was no coordination performed to assess peak or trough levels
in these patients.
The University of Michigan Institutional Review Board and the Washtenaw County
Community Mental Health Review Panel both approved the retrospective examination
of patient records for a comparison of service utilization 1 year before and 1 year after
the switch to generic clozapine. Since the decision to switch patients to generic cloza-
pine was not part of a research project, and the retrospective analysis of these data
would not identify the patients, informed consent was not required for this study.
Information about outpatient psychiatrist visits, psychiatric emergency room visits,
inpatient hospitalizations, crisis center utilization, clozapine dose (at switch and 1 year
later), and adjunct antipsychotics were collected from the medical record. Plasma
clozapine levels were compared using paired t-tests. Wilcoxon Signed Ranks tests were
used to compare inpatient hospital days, partial hospital admissions, psychiatric
emergency room visits, and outpatient psychiatrist visits in the year before, and the
year after, the switch to generic clozapine.
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RESULTS
One hundred and eight patients were on clozapine during the 2 year
period, and were included in the study. There were 62 men and 46
women, and the average age of the patients was 42.5 years. Ninety two
patients were white, two were Hispanic, and there were 14 African
Americans. No patient had to be withdrawn from generic clozapine
secondary to leucopenia or agranulocytosis. The average daily cloza-
pine dose was 452 ± 177 in December of 2000 and 452 ± 176 in
December of 2001 (df ¼ 106, t ¼ 0.42, p ¼ 0.97). Sixteen patients re-
quired an increase in their clozapine dose, 11 required a decrease in
dose, and 75 patients were on the same dose at the conclusion of 2001.
Nine patients required the addition of another antipsychotic, three
patients had a change of their adjunct antipsychotic, and six patients
were able to reduce the dose of their adjunct antipsychotic. Eighty six
patients had their plasma drawn 2 weeks before and after the switch to
generic clozapine, and there was no significant difference in plasma
levels (df 1,171, F ¼ 2.93, p ¼ N.S.) (Table 1). There were no significant
differences for inpatient hospital days (239 hospital days with Novartis
Clozaril, 101 hospital days with Mylan clozapine n ¼ 106, p ¼ 0.37),
crisis center admissions (24 admission with Novartis Clozaril, 17
admissions with Mylan clozapine, n ¼ 106, p ¼ 0.40), or outpatient
psychiatrist visits (590 visits with Novartis Clozaril, 567 visits with
Mylan clozapine n ¼ 106, p ¼ 0.84) (Table 1). There was a significant
decrease in psychiatric emergency room visits (69 visits with Novartis
Clozaril, 32 visits with Mylan clozapine, n ¼ 106, p ¼ 0.04) (Table 1).
DISCUSSION
These data demonstrate that there was no increase in service utiliza-
tion by patients who were converted to generic clozapine. In fact, all of
our measures of utilization decreased, although this decrease was sig-
nificant only for emergency room visits. Therefore, it is extremely un-
likely that our design merely failed to detect a small increase in
utilization. The lack of an increase in utilization is consistent with
previous reports by Makela et al. (2003) and Stoner et al. (2003) dem-
onstrating that patients switched to generic clozapine did not show a
deterioration in clinical status 2–4 months after the switch. Further,
Sajbel, Carter, and Wiley (2001) showed a lack of leucopenia or a need
to change clozapine dosages when patients were switched to Zenith
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Goldline Pharmaceuticals clozapine, which is also consistent with our
data. Although some reports have suggested that some patients have
symptom exacerbation after switching to generic clozapine (Kluznik
et al., 2001; Mofsen & Balter, 2001), our proxy measures of utilization
did not reflect increasing symptoms. However, because we did not as-
sess clinical status before and after the switch, it is possible that pa-
tients did exhibit symptom change with the switch.
Similarly, the lack of a change in utilization may reflect the gradual
stabilization of these patients over time, or the gradual reduction of
patients using inpatient or psychiatric emergency room services in
general (which is a goal in the treatment of the seriously and persis-
tently mentally ill). Our data do not address these points directly. Still,
these points do not detract from our conclusion that the switch to
Mylan generic clozapine did not lead to a service utilization increase
immediately after the switch.
TABLE 1
Service utilization and medication levels before and after
switching from brand-name (Novartis) to generic (Mylan)
clozapine
n Novartis Mylan p-value1
Service Utilization2
Inpatient hospital days 106 239 101 .37
Crises center admissions 106 24 17 .40
Outpatient physician
visits
106 590 567 .84
Psychiatric emergency
room visits




106 452 ± 177 452 ± 176 .97
Plasma clozapine level
(mean ± SD; ng/ml)4
86 599 ± 319 691 ± 383 .09
1Wilcoxon Signed Ranks test used in analyses of service utilization and t-tests used for medication
data.
2Service utilization was measured from January 1–December 31, 2000 for Novartis and from
January 1–December 31, 2001 for Mylan.
3Medication dose was ascertained just before the switch to generic clozapine and 1 year after.
4Plasma levels were measured 2 weeks before the switch to generic clozapine and 2 weeks after.
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Several studies have emphasized the importance of bioavailability
and medication tolerability when prescribing generic clozapine. Lam,
Ereshefsky, Toney, and Gonzales, (2001) found that 5 of 21 patients
had area under the concentration-time curve levels below the 80–120%
range when taking Zenith Goldline Pharmaceuticals generic clozapine,
suggesting a difference in bioavailability. Further, Cutler (2001)
showed that 6 of 30 patients had orthostatic hypotension when taking
Creighton generic clozapine. None of our patients had to stop generic
clozapine because of hypotension, but there was a statistically non-
significant increase in average clozapine plasma levels with Mylan
generic clozapine. Therefore, clinicians may want monitor plasma
clozapine levels if the emergence of dose-dependent side effects occurs.
Finally, Tse, Thompson, and Procyshyn (2003) emphasized that any
cost savings realized in converting to a less expensive formulation of an
antipsychotic cannot be lost by an increase in service utilization. We did
not find any increase in service utilization in this study, so pharmacy
savings do not appear to be lost due to compensatory increases in
service utilization.
In conclusion, there were no significant increases in mental health
service utilization after the conversion to Mylan generic clozapine. The
switch to Mylan generic clozapine was cost effective, as the reduction in
pharmacy costs was not offset by increased utilization costs.
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